Therefore, in this present study, we aimed to determine the effect of one commonly studied genetic polymorphism (SNP) from both the FADS1 and FADS2 gene on a surrogate measure of insulin resistance and lipid levels in a metabolically high-risk population of patients diagnosed with schizophrenia or bipolar disorder and largely exposed to AAPs. Here, FADS2 is linked to schizophrenia.